APO Research
Talk to an analyst

APO RESEARCH · REPORT

SGLT-2 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 2032

29 December 202590 pages

Choose your research edition.

Industry ResearchSGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment include Astellas, Boehringer Ingelheim, Chugai Pharmaceutical, Taisho Pharmaceutical, AstraZeneca, Jiangsu Hengrui Medicine, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The SGLT-2 Inhibitors for Type 2 Diabetes Treatment market size, estimates, and forecasts are presented in terms of sales volume (M Pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Company

Astellas

Boehringer Ingelheim

Chugai Pharmaceutical

Taisho Pharmaceutical

AstraZeneca

Jiangsu Hengrui Medicine

Merck

Johnson & Johnson

Sanofi

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Canagliflozin

Empagliflozin

Dapagliflozin

Others

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Canagliflozin Table 2. Major Company of Empagliflozin Table 3. Major Company of Dapagliflozin Table 4. Major Company of Others Table 5. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type (2021-2026) Table 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type (2021-2026) Table 10. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2026) & (US$/K Pcs) Table 11. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 12. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type (2027-2032) Table 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (US$ Million) Table 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type (2027-2032) Table 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2027-2032) & (US$/K Pcs) Table 16. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 17. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 18. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 19. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 21. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 23. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 25. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (US$ Million) Table 26. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 27. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 28. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 29. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Company (2021-2026) Table 32. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Company (2021-2026) & (M Pcs) Table 33. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Company (2021-2026) Table 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Price by Company (2021-2026) & (US$/K Pcs) Table 35. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Major Company Production Sites and Headquarters Table 37. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application Table 38. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 43. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Region (2021-2026) Table 44. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (US$ Million) Table 45. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Region (2021-2026) Table 46. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 47. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs) Table 48. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Region (2027-2032) Table 49. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (US$ Million) Table 50. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Region (2027-2032) Table 51. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Value (US$ Million), Price (US$/K Pcs) and Gross Margin (2027-2032) Table 52. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 54. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application (2021-2026) Table 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 56. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application (2021-2026) Table 57. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2026) & (US$/K Pcs) Table 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 59. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application (2027-2032) Table 60. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (US$ Million) Table 61. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application (2027-2032) Table 62. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2027-2032) & (US$/K Pcs) Table 63. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 64. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 65. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 66. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 68. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 70. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 72. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (US$ Million) Table 73. Astellas Company Information Table 74. Astellas Business Overview Table 75. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 76. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 77. Astellas Recent Development Table 78. Boehringer Ingelheim Company Information Table 79. Boehringer Ingelheim Business Overview Table 80. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 82. Boehringer Ingelheim Recent Development Table 83. Chugai Pharmaceutical Company Information Table 84. Chugai Pharmaceutical Business Overview Table 85. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 86. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 87. Chugai Pharmaceutical Recent Development Table 88. Taisho Pharmaceutical Company Information Table 89. Taisho Pharmaceutical Business Overview Table 90. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 91. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 92. Taisho Pharmaceutical Recent Development Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 96. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 97. AstraZeneca Recent Development Table 98. Jiangsu Hengrui Medicine Company Information Table 99. Jiangsu Hengrui Medicine Business Overview Table 100. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 101. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 102. Jiangsu Hengrui Medicine Recent Development Table 103. Merck Company Information Table 104. Merck Business Overview Table 105. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 106. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 107. Merck Recent Development Table 108. Johnson & Johnson Company Information Table 109. Johnson & Johnson Business Overview Table 110. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 111. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 112. Johnson & Johnson Recent Development Table 113. Sanofi Company Information Table 114. Sanofi Business Overview Table 115. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 116. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 117. Sanofi Recent Development Table 118. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 119. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 120. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 121. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 122. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 123. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 125. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 126. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 128. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 129. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 130. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 131. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 132. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 133. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 136. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 140. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 141. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 142. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 146. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 148. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 149. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 150. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 151. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 152. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 153. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 156. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 158. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (M Pcs): 2021 VS 2025 VS 2032 Table 159. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 160. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2021-2026) Table 161. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032) & (M Pcs) Table 162. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share Forecast by Country (2027-2032) Table 163. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country (2021-2026) Table 166. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share Forecast by Country (2027-2032) Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 171. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Image Figure 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 5. Canagliflozin Image Figure 6. Global Canagliflozin Sales YoY Growth (2021-2032) & (M Pcs) Figure 7. Empagliflozin Image Figure 8. Global Empagliflozin Sales YoY Growth (2021-2032) & (M Pcs) Figure 9. Dapagliflozin Image Figure 10. Global Dapagliflozin Sales YoY Growth (2021-2032) & (M Pcs) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (M Pcs) Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Type 2025 VS 2032 Figure 15. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 16. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 17. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 18. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 21. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 22. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. E-commerce and Internet Medical Care Image Figure 28. Global E-commerce and Internet Medical Care Sales YoY Growth (2021-2032) & (M Pcs) Figure 29. Offline Retail Pharmacy Image Figure 30. Global Offline Retail Pharmacy Sales YoY Growth (2021-2032) & (M Pcs) Figure 31. Hospitals and Clinics Image Figure 32. Global Hospitals and Clinics Sales YoY Growth (2021-2032) & (M Pcs) Figure 33. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Application 2025 VS 2032 Figure 35. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 36. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 37. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 38. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 41. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 42. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share in Value by Application in 2025 Figure 45. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 46. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 50. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 54. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 58. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Figure 62. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Empagliflozin
  • Dapagliflozin
  • Others
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • Astellas
  • Boehringer Ingelheim
  • Chugai Pharmaceutical
  • Taisho Pharmaceutical
  • AstraZeneca
  • Jiangsu Hengrui Medicine
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Type
  6. 1.3.1 Canagliflozin
  7. 1.3.2 Empagliflozin
  8. 1.3.3 Dapagliflozin
  9. 1.3.4 Others
  10. 1.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  11. 1.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2026)
  2. 3.2 Global Top Players by SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2026)
  3. 3.3 Global Top Players by SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (2021-2026)
  4. 3.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Major Company Production Sites & Headquarters
  6. 3.6 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company, Product Type & Application
  7. 3.7 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3
4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Regional Status and Outlook
  1. 4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Historic Market Size by Region
  3. 4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales in Value by Region (2021-2026)
  5. 4.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Region
  7. 4.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales in Value by Region (2027-2032)
  9. 4.3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application
  1. 5.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Application
  2. 5.1.1 E-commerce and Internet Medical Care
  3. 5.1.2 Offline Retail Pharmacy
  4. 5.1.3 Hospitals and Clinics
  5. 5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Astellas
  2. 6.1.1 Astellas Company Information
  3. 6.1.2 Astellas Business Overview
  4. 6.1.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 6.1.5 Astellas Recent Developments
  7. 6.2 Boehringer Ingelheim
  8. 6.2.1 Boehringer Ingelheim Company Information
  9. 6.2.2 Boehringer Ingelheim Business Overview
  10. 6.2.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 6.2.5 Boehringer Ingelheim Recent Developments
  13. 6.3 Chugai Pharmaceutical
  14. 6.3.1 Chugai Pharmaceutical Company Information
  15. 6.3.2 Chugai Pharmaceutical Business Overview
  16. 6.3.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 6.3.5 Chugai Pharmaceutical Recent Developments
  19. 6.4 Taisho Pharmaceutical
  20. 6.4.1 Taisho Pharmaceutical Company Information
  21. 6.4.2 Taisho Pharmaceutical Business Overview
  22. 6.4.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 6.4.5 Taisho Pharmaceutical Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Jiangsu Hengrui Medicine
  32. 6.6.1 Jiangsu Hengrui Medicine Company Information
  33. 6.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 6.6.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 6.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Johnson & Johnson
  44. 6.8.1 Johnson & Johnson Company Information
  45. 6.8.2 Johnson & Johnson Business Overview
  46. 6.8.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 6.8.5 Johnson & Johnson Recent Developments
  49. 6.9 Sanofi
  50. 6.9.1 Sanofi Company Information
  51. 6.9.2 Sanofi Business Overview
  52. 6.9.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 6.9.5 Sanofi Recent Developments
7 North America by Country
  1. 7.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 7.1.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 7.1.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 7.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 7.2.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 7.2.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 8.1.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 8.1.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 8.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 8.2.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 8.2.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 9.1.1 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 9.2.1 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 10.1.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 10.1.3 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 10.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 10.2.1 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 10.2.3 South America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country
  2. 11.1.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  6. 11.2.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 12.1.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
  7. 12.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
  10. 12.2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst